Pneumococcal antibodies in a child with type 14 pneumococcal conjugate vaccine failure

被引:11
作者
O'Brien, Katherine L. [1 ]
Moisi, Jennifer [1 ]
Romero-Steiner, Sandra [2 ]
Holder, Patricia [2 ]
Carlone, George M. [2 ]
Reid, Raymond [1 ]
Santosham, Mathuram [1 ]
机构
[1] Johns Hopkins Bloomberg Sch Med, Ctr Amer Indian Hlth, Baltimore, MD USA
[2] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA
基金
美国国家卫生研究院;
关键词
Streptococcus pneumoniae; Pneumococcal conjugate vaccine; Immunogenicity; Vaccine failure; STREPTOCOCCUS-PNEUMONIAE; IMMUNOGENICITY; EFFICACY; INFANTS; SAFETY; SERUM;
D O I
10.1016/j.vaccine.2008.12.060
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We measured the concentration, opsonic activity, and avidity of serotype-specific serum antibodies in a pneumococcal conjugate vaccine (PnCRM7) efficacy trial participant who contracted serotype 14 pneumococcal bacteremia following dose 3 of PnCRM7. Controls included 18 PnCRM7- and 10 MnCC-vaccinated children without invasive pneumococcal disease (IPD). The child with vaccine failure had 4.98 mcg/mL of serotype 14 antibodies 10 days before disease onset; these antibodies had greater opsonic activity and lower avidity than those of control PnCRM7 recipients. The child had no booster response to a fourth dose of PnCRM7 for most vaccine serotypes. We conclude that antibody concentration, functional activity and avidity do not predict individual protection against IPD, and immunological correlates of protection are only useful at the population level. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1863 / 1868
页数:6
相关论文
共 20 条
[1]  
Addae-Mensah I, 2005, WHO TECH REP SER, V929, P1
[2]  
Angoulvant FO, 2005, CLIN INFECT DIS, V40, P494
[3]  
Anttila M, 1999, CLIN EXP IMMUNOL, V118, P402
[4]   Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom [J].
Auckland, Cressida ;
Gray, Stephen ;
Borrow, Ray ;
Andrews, Nick ;
Goldblatt, David ;
Ramsay, Mary ;
Miller, Elizabeth .
JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (12) :1745-1752
[5]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[6]   Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults:: A longitudinal household study [J].
Goldblatt, D ;
Hussain, M ;
Andrews, N ;
Ashton, L ;
Virta, C ;
Melegaro, A ;
Pebody, R ;
George, R ;
Soininen, A ;
Edmunds, J ;
Gay, N ;
Kayhty, H ;
Miller, E .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (03) :387-393
[7]   Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa [J].
Huebner, RE ;
Mbelle, N ;
Forrest, B ;
Madore, DV ;
Klugman, KP .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (11) :1004-1007
[8]   Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants [J].
Jódar, L ;
Butler, J ;
Carlone, G ;
Dagan, R ;
Goldblatt, D ;
Käyhty, H ;
Klugman, K ;
Plikaytis, B ;
Siber, G ;
Kohberger, R ;
Chang, I ;
Cherian, T .
VACCINE, 2003, 21 (23) :3265-3272
[9]   Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae [J].
Kim, JO ;
Romero-Steiner, S ;
Sorensen, UBS ;
Blom, J ;
Carvalho, M ;
Barnard, S ;
Carlone, G ;
Weiser, JN .
INFECTION AND IMMUNITY, 1999, 67 (05) :2327-2333
[10]   A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection [J].
Klugman, KP ;
Madhi, SA ;
Huebner, RE ;
Kohberger, R ;
Mbelle, N ;
Pierce, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (14) :1341-1348